Using Post-Grant Proceedings To Challenge Pharma Patents
Law360, New York (August 25, 2014, 11:45 AM EDT) -- Thanks to the Leahy-Smith America Invents Act, there are now a variety of ways to challenge the validity of a U.S. patent, such as inter partes reviews, covered business method proceedings, postgrant reviews, derivation proceedings and ex parte re-exams. It is still early in the game for many of these proceedings, and it can be difficult for a company to establish a strategy for challenging a patent, particularly in the biological/pharmaceutical space, since far fewer PTAB postgrant proceedings to date have involved biological/pharmaceutical patents than electrical/computer patents. Still, some conventional wisdom is beginning to emerge about this array of options, including whether and how...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!